Literature DB >> 15317466

Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.

Roberto Pellicciari1, Gabriele Costantino, Emidio Camaioni, Bahman M Sadeghpour, Antonio Entrena, Timothy M Willson, Stefano Fiorucci, Carlo Clerici, Antimo Gioiello.   

Abstract

The farnesoid X receptor (FXR) is activated by endogenous bile acids (BAs) and plays a variety of physiological roles related to modulation of gene transcription. In particular, FXR positively regulates the cholesterol catabolism while feedback inhibits the BA synthesis by repressing the expression of the CYP7A and CYP8B genes. We have previously shown that 6alpha-ethyl-CDCA (6ECDCA) is a potent and selective FXR agonist. In this paper we report an extensive structure-activity relationship for a series of synthetic bile acids. Our results indicate that the 6alpha position plays a fundamental role in determining affinity and that the side chain of BA is amenable to a variety of chemical modification. Although none of the new derivatives is more potent than 6ECDCA, we show here that a wide variability in efficacy, from full agonists to partial antagonists, can be obtained.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15317466     DOI: 10.1021/jm049904b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  49 in total

Review 1.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

Review 2.  Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.

Authors:  Gustav Paumgartner
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 3.  FXR Agonists: From Bench to Bedside, a Guide for Clinicians.

Authors:  Ahmad Samer Alawad; Cynthia Levy
Journal:  Dig Dis Sci       Date:  2016-10-12       Impact factor: 3.199

4.  Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.

Authors:  Shinobu Miyazaki-Anzai; Moshe Levi; Adelheid Kratzer; Tabitha C Ting; Linda B Lewis; Makoto Miyazaki
Journal:  Circ Res       Date:  2010-04-29       Impact factor: 17.367

Review 5.  New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.

Authors:  Natalia Pydyn; Katarzyna Miękus; Jolanta Jura; Jerzy Kotlinowski
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

Review 6.  FXR signaling in the enterohepatic system.

Authors:  Tsutomu Matsubara; Fei Li; Frank J Gonzalez
Journal:  Mol Cell Endocrinol       Date:  2012-05-17       Impact factor: 4.102

7.  Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH.

Authors:  Hualing Xiao; Peng Li; Xiaolin Li; Haiying He; Jianhua Wang; Fengxun Guo; Jiliang Zhang; Luxia Wei; Hongmei Zhang; Yueyuan Shi; Lijuan Hou; Liang Shen; Zhengxia Chen; Chunyan Du; Shouliang Fu; Pengtao Zhang; Fei Hao; Ping Wang; Deming Xu; Wei Liang; Xin Tian; Aiming Zhang; Xingdong Cheng; Ling Yang; Xiangjian Wang; Xiquan Zhang; Jian Li; Shuhui Chen
Journal:  ACS Med Chem Lett       Date:  2017-10-31       Impact factor: 4.345

8.  Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.

Authors:  Matteo Incerti; Massimiliano Tognolini; Simonetta Russo; Daniele Pala; Carmine Giorgio; Iftiin Hassan-Mohamed; Roberta Noberini; Elena B Pasquale; Paola Vicini; Silvia Piersanti; Silvia Rivara; Elisabetta Barocelli; Marco Mor; Alessio Lodola
Journal:  J Med Chem       Date:  2013-03-22       Impact factor: 7.446

Review 9.  Nuclear receptors in bile acid metabolism.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Drug Metab Rev       Date:  2013-02       Impact factor: 4.518

Review 10.  Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.

Authors:  M Noureddin; Q M Anstee; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2016-04-08       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.